Merel Opdam

9PUBLICATIONS
16CO-AUTHORS
Cardiology (incl. cardiovascular diseases)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Clinical pharmacology and therapeuticsRespiratory diseasesBehavioural epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Aug 13, 2025
Ischaemic cardiovascular risk with allopurinol and protective effect of colchicine in gout: a Dutch nationwide pharmaco-epidemiological study.

Iris Rose Peeters, Maike H M Wientjes, Isla S Mackenzie

|Aug 12, 2025
Continuation Versus Temporary Interruption of Immunomodulatory Agents During Infections in Patients With Inflammatory Rheumatic Diseases: A Randomized Controlled Trial.

Merel A A Opdam, Nathan den Broeder, Reinout van Crevel

|May 04, 2024
Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs.

M A A Opdam, N den Broeder, B J F van den Bemt

|Oct 05, 2023
Therapy with JAK inhibitors or bDMARDs and the risk of cardiovascular events in the Dutch rheumatoid arthritis population.

Calin D Popa, Merel A A Opdam, Nathan den Broeder

|Sep 27, 2023
Preferences of Patients With Musculoskeletal Disorders Regarding the Timing and Channel of eHealth and Factors Influencing Its Use: Mixed Methods Study.

Jeffrey van der Ven, Bart J F van den Bemt, Liset van Dijk

|Jul 06, 2023
Infection incidence, timing and dose dependency in rheumatoid arthritis patients treated with rituximab: a retrospective cohort study.

Lara D Veeken, Merel A A Opdam, Lise M Verhoef

Pageof 2

Frequent Collaborators

2 joint publications

Reinout van Crevel

2 joint publications

Nathan den Broeder

2 joint publications

Lise M Verhoef

2 joint publications

Alfons A den Broeder